Date Published 
December 2013

Page Count
93

Additional Info 
Single-site, country, and global licenses are multi-user, searchable, and cut-and-paste ready PDFs delivered by e-mail.

 Prenatal Diagnostics Europe 

For Corporate Subscriptions, Multi-Reports Orders, Discounts or Order Questions.  

Contact:
Kerri Kelley
Customer Service
781-972-1347 


IPR-Bundle-Button 

Prenatal Diagnostic Testing - Overview

[ektdesignns_placeholder_ID0EF] 

 

New to Insight Pharma Reports is Prenatal Diagnostics: Invasive testing, noninvasive testing, and rising maternal screening methods for preeclampsia and preterm labor. This report discusses improvements in invasive procedures (karyotyping vs. cytogenetics), and the rise of noninvasive screening methods and their impact on prenatal healthcare. Although covering standard invasive procedure, this report focuses on the noninvasive technologies either on the market or in development.

Report Highlights:

  • Exclusive interviews with CEOs, CSOs, and Vice Presidents from Sequenom, Verinata Health, Ariosa Diagnostics, Natera, Silicon Biosystems, Metabolomic Diagnostics and NX PharmaGen
  • Specifications of particular instruments
  • Company goals, customer feedback, challenges encountered, competitive advantage, platform pricing, and future endeavors.
  • A survey capturing the demographics of the prenatal industry is presented at the end of the report, specifically highlighting organizational background, areas of research, challenges encountered, and applications in development. 
  • Directory of companies within Prenatal Diagnostics